NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
TAL Education Group (NYSE: TAL)
Class Period: April 26, 2018 to June 13, 2018
Lead Plaintiff Deadline: August 17, 2018
TAL Education Group allegedly made materially false and/or misleading statements and/or failed to disclose that:
(1) the Company overstated its net income; (2) the Company's net income was deteriorating; and (3) as a result of the foregoing,
Defendants' statements about TAL's business, operations, and prospects, were materially false and/or misleading and/or lacked a
reasonable basis.
Get additional information about the TAL lawsuit: http://www.kleinstocklaw.com/pslra-c/tal-education-group?wire=3
Deutsche Bank Aktiengesellschaft (NYSE: DB)
Class Period: March 20, 2017 to May 30, 2018
Lead Plaintiff Deadline: August 6, 2018
The complaint alleges that throughout the class period Deutsche Bank Aktiengesellschaft made materially false
and/or misleading statements and/or failed to disclose that: (1) Deutsche Bank's internal control environment and infrastructure
were materially weak and deficient; and (2) as a result, Deutsche Bank's statements about the Company's business and operations
were materially false and misleading at all relevant times.
On May 31, 2018, The Wall Street Journal reported that the U.S. Federal Reserve had designated Deutsche Bank’s
U.S. business as being in a “trouble condition,” citing concerns about “its controls around measuring financial exposure to clients
and valuing collateral that backed loans.” It was also reported that the Federal Deposit Insurance Corporation (“FDIC”) added
Deutsche Bank’s FDIC-insured subsidiary, Deutsche Bank Trust Company Americas, to a list of “problem banks” which are at-risk. On
this news, Deutsche Bank’s share price fell $0.49 or over 4% to close at $11.08 on May 31, 2018.
Get additional information about the DB lawsuit: http://www.kleinstocklaw.com/pslra-c/deutsche-bank-aktiengesellschaft-2?wire=3
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH)
Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13,
2018
Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000
patients to 1,200 patients to meet the trial's primary endpoints; (2) the enrollment of more patients in the trial indicated that
the existing population was inadequate to meet the trial's primary endpoints; and (3) consequently, Defendants' statements about
Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Get additional information about the TTPH lawsuit: http://www.kleinstocklaw.com/pslra-c/tetraphase-pharmaceuticals-inc?wire=3
AbbVie Inc. (NYSE: ABBV)
Class Period: May 30, 2018
Lead Plaintiff Deadline: September 24, 2018
Throughout the class period, AbbVie Inc. allegedly made materially false and/or misleading statements and/or
failed to disclose that: The complaint alleges that AbbVie issued false and misleading statements, in both press releases and
filings with the U.S. Securities and Exchange Commission, regarding the results of the Company's $7.5 billion modified Dutch
auction tender offer that expired on May 29, 2018 (the "Tender Offer"). Specifically, the complaint alleges that before the opening
of trading on May 30, 2018, the Company announced that it expected to acquire 71.4 million of its shares tendered at or below $105
per share. As a result of this news, the price of AbbVie securities significantly increased. However, after the close of trading on
May 30, 2018, the Company released materially different results for the Tender Offer due to certain omissions, announcing that the
Company expected to acquire only those shares tendered at or below $103 per share. Upon this news, AbbVie shares fell from a close
of $103.01 per share on May 30, 2018, to a close of $98.94 on May 31, 2018.
Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-c/abbvie-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
